Erectile Dysfunction Global Market Report 2025

The erectile dysfunction market size has grown strongly in recent years. It will grow from $2.46 billion in 2024 to $2.69 billion in 2025 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period was driven by the increasing incidence of cardiovascular diseases, the rising prevalence of diabetes, greater awareness of erectile dysfunction as a medical condition, an aging population contributing to higher ED cases, and a growing preference for personalized treatment options.

The erectile dysfunction market size is expected to see strong growth in the next few years. It will grow to $3.78 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period is expected to be driven by an increase in psychological factors, higher rates of obesity and metabolic disorders, rising demand for non-invasive erectile dysfunction treatments, a growing number of patient consultations for sexual health, and increasing government initiatives promoting men’s health and addressing lifestyle-related risk factors. Key trends include the expansion of e-pharmacies for erectile dysfunction drugs, advancements in penile implant technologies, technological innovations in erectile dysfunction diagnostics, the development of novel treatment methods targeting the root causes of ED, and the introduction of more effective phosphodiesterase type 5 inhibitors.

The increasing prevalence of lifestyle-related diseases is expected to drive growth in the erectile dysfunction market. Lifestyle-related diseases are primarily caused by unhealthy habits such as poor diet, lack of physical activity, smoking, and excessive alcohol consumption. Factors contributing to the rise in these conditions include increased sedentary behavior, poor dietary choices, stress, and unhealthy habits. Erectile dysfunction (ED) is often an early indicator of lifestyle-related diseases, including cardiovascular conditions and diabetes, emphasizing the importance of timely medical intervention and healthier lifestyle changes. For example, in May 2022, the World Obesity Federation, a UK-based non-profit organization, reported that by 2030, one billion people worldwide equivalent to one in five women and one in seven men are projected to be living with obesity. This figure is expected to rise to four billion people, or 51% of the global population, who will be either overweight or obese by 2035. The increasing prevalence of lifestyle-related diseases is, therefore, expected to drive the growth of the erectile dysfunction market.

Leading companies in the erectile dysfunction market are focusing on developing innovative products, such as over-the-counter (OTC) gels, to provide more accessible and convenient treatment options for individuals with ED. This approach aims to expand market reach and address unmet patient needs. An OTC gel is a topical medication available without a prescription, applied directly to the skin to treat specific conditions. For instance, in September 2024, Haleon plc, a UK-based consumer healthcare company, introduced Eroxon, the first FDA-cleared over-the-counter gel for erectile dysfunction. This groundbreaking product offers a non-invasive, fast-acting solution designed to improve accessibility and convenience for patients. Its topical application eliminates the need for oral medications, reducing potential systemic side effects and providing an alternative treatment option.

In September 2022, Advanced MedTech Holdings, a Singapore-based medical device company, acquired Shenzhen Wikkon Medical Apparatus Co. Ltd. for an undisclosed amount. This acquisition strengthens Advanced MedTech Holdings’ presence in the urology sector in China by leveraging Wikkon's expertise in developing and manufacturing urology and shock wave therapy devices. Shenzhen Wikkon Medical Apparatus Co. Ltd., a China-based company, specializes in extracorporeal shock wave therapy (ESWT) for treating conditions such as erectile dysfunction and urinary stones.

Major players in the erectile dysfunction market are Pfizer Inc., Bayer AG, Dong-A Socio Holdings Co. Ltd., Sanofi S.A., GlaxoSmithKline plc, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Limited, Boston Scientific Corporation, Sandoz International GmbH, Sun Pharmaceutical Industries Limited, Coloplast Corporation, Dr. Reddy's Laboratories Limited, Cipla Limited, Ferring Pharmaceuticals A/S, Endo International plc, Zydus Lifesciences Limited, Lupin Limited, Hims & Hers Health Inc., Cadila Pharmaceuticals Limited, VIVUS Inc., Rigicon Inc., Petros Pharmaceuticals Inc., Futura Medical plc, Apricus Biosciences Inc., Pos-T-Vac Medical Inc., Initiator Pharma A/S.

North America was the largest region in the erectile dysfunction market in 2024. The regions covered in erectile dysfunction report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the erectile dysfunction market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Erectile dysfunction (ED) is the inability to achieve or sustain an erection adequate for satisfactory sexual performance. It is a prevalent condition influenced by physical, psychological, and lifestyle factors, impacting men's overall well-being and quality of life.

The primary product categories for erectile dysfunction include drugs and devices. Drugs are chemical formulations designed to improve blood flow to the penis, enabling men to attain and maintain an erection. These products are distributed through hospital pharmacies, retail pharmacies, and online channels, serving end users such as hospitals and clinics, ambulatory surgery centers, pharmacies, and other healthcare providers.

The erectile dysfunction market research report is one of a series of new reports that provides erectile dysfunction market statistics, including erectile dysfunction industry global market size, regional shares, competitors with an erectile dysfunction market share, detailed erectile dysfunction market segments, market trends and opportunities, and any further data you may need to thrive in the erectile dysfunction industry. This erectile dysfunction market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The erectile dysfunction market consists of sales of medications, devices, and therapies aimed at treating erectile dysfunction. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.